{"nctId":"NCT02168491","briefTitle":"Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin","startDateStruct":{"date":"2014-11"},"conditions":["Type 2 Diabetes Mellitus"],"count":10,"armGroups":[{"label":"Intervention group","type":"EXPERIMENTAL","interventionNames":["Drug: Lixisenatide","Drug: Insulin glargine"]}],"interventions":[{"name":"Lixisenatide","otherNames":["Lyxumia"]},{"name":"Insulin glargine","otherNames":["Lantus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 - 70a\n* Subjects understand study related activities and give written informed concent\n* HbA1c between 7 - 10 % under treatment with premixed insulin (2-3 injections)\n\nExclusion Criteria:\n\n* Females of child-bearing age\n* History of hypoglycemia unawareness\n* Gastrointestinal disease associated with prolonged nausea and vomiting\n* Impaired liver function (transaminase \\>2x than normal)\n* Impaired kidney function (creatinin \\> 1,2 mg/dl)\n* Known intolerance against GLP-1 receptor agonists\n* History of pancreatitis or pancreas tumor\n* Malignancies, autoimmune diseases\n* Severe dyslipidemia (serum triglycerides \\> 400 mg/dl, cholesterol \\> 300 mg/dl)\n* Psychiatric disorder\n* Oral glucose lowering medication except for metformin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to End","description":"A change between two time points is reported. Time Frame: baseline and 12 weeks.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG, Mean Over 2 Weeks)","description":"Patients will be instructed to record all insulin injections and a complete 7-point-blood glucose profile (fasting, 2h after breakfast, before lunch, 2h after lunch, before dinner, 2h after dinner, late before going to bed) during a one-week prestudy run-in period to confirm compliance and document current metabolic control and doses of premixed insulin.\n\nPatients will be asked to record not only glucose profiles (at least 4 measurements per day) but also the occurrence of hypoglycemic symptoms or other adverse effects daily throughout the study.\n\nDuring the last week of the study patients will be asked to again record a complete 7-point-blood glucose profile (fasting, 2h after breakfast, before lunch, 2h after lunch, before dinner, 2h after dinner, late before going to bed) and drug injections to confirm compliance and document metabolic control.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to End of Study","description":"A change between two time points is reported. Time Frame: baseline and 12 weeks.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"3.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["mild asymptomatic hypoglycaemia","mild gastrointestinal complaints","urinary tract infection","hypercholesterolaemia","symptomatic hypoglycaemia"]}}}